STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90α and β in multiple myeloma cells, which critically contribute to tumor-cell survival

被引:130
作者
Chatterjee, Manik
Jain, Sarika
Stuehmer, Thorsten
Andrulis, Mindaugas
Ungethuem, Ute
Kuban, Ralf-Juergen
Lorentz, Heike
Bommert, Kurt
Topp, Max
Kraemer, Doris
Mueller-Hermelink, Hans Konrad
Einsele, Hermann
Greiner, Axel
Bargou, Ralf C.
机构
[1] Univ Hosp Wurzburg, Div Hematol, Dept Internal Med 2, D-97080 Wurzburg, Germany
[2] Max Delbruck Ctr Mol Med, Robert Rossle Canc Clin, Berlin, Germany
[3] Univ Hosp Wurzburg, Inst Pathol, D-97080 Wurzburg, Germany
[4] Univ Med Berlin, Charite, Lab Funct Genom, Berlin, Germany
关键词
D O I
10.1182/blood-2006-05-024372
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The combined blockade of the IL-6R/STAT3 and the MAPK signaling pathways has been shown to inhibit bone marrow microenvironment (BMM)-mediated survival of multiple myeloma (MM) cells. Here, we identify the molecular chaperones heat shock proteins (Hsp) 90 alpha and beta as target genes of both pathways. The siRNA-mediated knockdown of Hsp90 or treatment with the novel Hsp90 inhibitor 17-DMAG attenuated the levels of STAT3 and phospho-ERK and decreased the viability of MM cells. Although knockdown of Hsp90 beta-unlike knockdown of Hsp90 alpha-was sufficient to induce apoptosis, this effect was strongly increased when both Hsp90s were targeted, indicating a cooperation of both. Given the importance of the BMM for drug resistance and MM-cell survival, apoptosis induced by Hsp90 inhibition was not mitigated in the presence of bone marrow stromal cells, osteoclasts, or endothelial cells. These observations suggest that a positive feedback loop consisting of Hsp90 alpha/beta and major signaling pathways supports the survival of MM cells. Finally, in situ overexpression of both Hsp90 proteins was observed in most MMs but not in monoclonal gammopathy of undetermined significance (MGUS) or in normal plasma cells. Our results underpin a role for Hsp90 alpha, and beta in MM pathogenesis. (c) 2007 by The American Society of Hematology
引用
收藏
页码:720 / 728
页数:9
相关论文
共 39 条
[1]   Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion [J].
Abe, M ;
Hiura, K ;
Wilde, J ;
Shioyasono, A ;
Moriyama, K ;
Hashimoto, T ;
Kido, S ;
Oshima, T ;
Shibata, H ;
Ozaki, S ;
Inoue, D ;
Matsumoto, T .
BLOOD, 2004, 104 (08) :2484-2491
[2]   Extrafollicular proliferation of B cells in the absence of follicular hyperplasia:: a distinct reaction pattern in lymph nodes correlated with primary or recall type responses [J].
Brighenti, A ;
Andrulis, M ;
Geissinger, E ;
Roth, S ;
Müller-Hermelink, HK ;
Rüdiger, T .
HISTOPATHOLOGY, 2005, 47 (01) :90-100
[3]   A system for stable expression of short interfering RNAs in mammalian cells [J].
Brummelkamp, TR ;
Bernards, R ;
Agami, R .
SCIENCE, 2002, 296 (5567) :550-553
[4]  
Buckley Katherine A, 2005, Methods Mol Med, V107, P55
[5]   Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells [J].
Chatterjee, M ;
Stühmer, T ;
Herrmann, P ;
Bommert, K ;
Dörken, B ;
Bargou, RC .
BLOOD, 2004, 104 (12) :3712-3721
[6]   In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp 130/STAT3 pathway [J].
Chatterjee, M ;
Hönemann, D ;
Lentzsch, S ;
Bommert, K ;
Sers, C ;
Herrmann, P ;
Mathas, S ;
Dörken, B ;
Bargou, RC .
BLOOD, 2002, 100 (09) :3311-3318
[7]   Antiapoptotic function of Bcl-2 in mast cells is dependent on its association with heat shock protein 90β [J].
Cohen-Saidon, C ;
Carmi, I ;
Keren, A ;
Razin, E .
BLOOD, 2006, 107 (04) :1413-1420
[8]   The 90-kDa molecular chaperone family:: Structure, function, and clinical applications.: A comprehensive review [J].
Csermely, P ;
Schnaider, T ;
Soti, C ;
Prohászka, Z ;
Nardai, G .
PHARMACOLOGY & THERAPEUTICS, 1998, 79 (02) :129-168
[9]   Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats [J].
Egorin, MJ ;
Lagattuta, TF ;
Hamburger, DR ;
Covey, JM ;
White, KD ;
Musser, SM ;
Eiseman, JL .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2002, 49 (01) :7-19
[10]   Pharmacokinetics and pharmacodynamics of 17-demethoxy 17-[[(2-dimethylamino)ethyl]amino]geldanamycin (17DMAG, NSC 707545) in C.B-17 SCID mice bearing MDA-MB-231 human breast cancer xenografts [J].
Eiseman, JL ;
Lan, J ;
Lagattuta, TF ;
Hamburger, DR ;
Joseph, E ;
Covey, JM ;
Egorin, MJ .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2005, 55 (01) :21-32